Clinical trials: Neuroendocrine Tumor Metastatic
Metastatic Merkel Cell Carcinoma
A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma (MCC).
- Trial name
- NCT03599713
- Testing
- Retifanlimab
- Where
- 65 sites in United States, Australia and 10 more
- Volunteers
- 107 people
- Sponsor
- Incyte Corporation
Neuroendocrine Carcinoma
Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma
The study will be conducted to compare the safety and efficacy of irinotecan combined with cisplatin (IP regimen) and etoposide combined with cisplatin (EP regimen) in advanced or metastatic gastrointestinal pancreatic and…
- Trial name
- NCT03168594
- Testing
- irinotecan cisplatin, Etoposide cisplatin
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Peking University
Metastatic Melanoma
IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma
This is a phase Ib, open label clinical study to evaluate the safety, tolerability, PK and antitumor activities of IN10018 as monotherapy and in combination with cobimetinib in subjects with metastatic uveal melanoma and…
- Trial name
- NCT04109456
- Testing
- IN10018, Cobimetinib, Atezolizumab
- Where
- 8 sites in United States, Australia
- Volunteers
- 51 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Melanoma, Skin Cancer
Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma
The investigators want to learn to predict which tumors will respond to CVT chemotherapy. CVT is a combination of three drugs - cisplatin, vinblastine, and temozolomide.
- Trial name
- NCT00885534
- Testing
- Cisplatin, Vinblastine, Temozolomide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Melanoma, Stage IV Melanoma
Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations
This phase II trial studies intermittent dosing of BRAF inhibitor LGX818 (encorafenib) and MEK inhibitor MEK 162 (binimetinib) in treating patients with melanoma that has spread to other parts of the body (metastatic) and have a…
- Trial name
- NCT02263898
- Testing
- Raf kinase inhibitor LGX818, binimetinib, laboratory biomarker analysis
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Melanoma
LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma
The primary purpose of the Phase II CLGX818X2102 study is to assess the anti-tumor activity of LGX818 in combination with selected agents.
- Trial name
- LOGIC (NCT01820364)
- Testing
- LGX818
- Where
- 6 sites in United States, Australia and 4 more
- Volunteers
- 15 people
- Sponsor
- Array BioPharma
Metastatic Uveal Melanoma, Cutaneous Melanoma
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including…
- Conditions
- Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
- Trial name
- NCT03947385
- Testing
- IDE196, Binimetinib, Crizotinib
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 336 people
- Sponsor
- IDEAYA Biosciences
Melanoma
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
This Phase II study is designed to evaluate the anti-tumor activity of three dose groups of SB-485232 (0.01, 0.1, and 1.0 mg/kg/day) administered intravenously as a single agent in subjects with previously untreated metastatic…
- Trial name
- NCT00107718
- Testing
- SB-485232
- Where
- 20 sites in United States, Australia
- Volunteers
- 64 people
- Sponsor
- GlaxoSmithKline
Melanoma
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
The purpose of this clinical study is to examine the safety, immunogenicity and clinical activity of the immunotherapeutic product GSK2302025A (also referred to as recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic [ASCI])…
- Trial name
- NCT01149343
- Testing
- Immunotherapeutic GSK2302025A, different formulations
- Where
- 37 sites in Czechia, France and 4 more
- Volunteers
- 107 people
- Sponsor
- GlaxoSmithKline
Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Cancer
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer
The purpose of this study is to evaluate the safety and efficacy of a combination of nivolumab, ipilimumab, cabazitaxel and carboplatin in men with neuroendocrine prostate cancer (NEPC) or other aggressive variants of prostate…
- Trial name
- CHAMP (NCT04709276)
- Testing
- Nivolumab, Ipilimumab, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Andrew J. Armstrong, MD
Solid Organ Cancers
GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers
The purpose of this study is to evaluate the safety of the investigational product GL-ONC1. GL-ONC1, a vaccinia virus, has been genetically modified for use as a potential anti-cancer drug to destroy cancer cells.
- Trial name
- NCT02714374
- Testing
- GL-ONC1
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Andrew Lowy
Non-hematologic Malignancies, Metastatic Melanoma
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Temozolomide (chemotherapy) in treating patients with solid tumors, including metastatic melanoma (MM), BRCA deficient…
- Conditions
- Non-hematologic Malignancies, Metastatic Melanoma, Breast Cancer, Ovarian Cancer
- Trial name
- NCT00526617
- Testing
- ABT-888, Temozolomide
- Volunteers
- 41 people
- Sponsor
- AbbVie
Recurrent Melanoma, Recurrent Pancreatic Cancer
APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of small interfering ribonucleic acid (siRNA)-transfected peripheral blood mononuclear cells APN401 (APN401) in treating patients with melanoma, kidney, or pancreatic…
- Conditions
- Recurrent Melanoma, Recurrent Pancreatic Cancer, Recurrent Renal Cell Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT02166255
- Testing
- siRNA-transfected peripheral blood mononuclear cells APN401, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Wake Forest University Health Sciences
Metastatic Cancer
Genetically-informed Therapies for Patients With Metastatic Cancer
Genetic mutations associated with cancer are being discovered and new treatments are being created to treat people whose cancer tumors have certain genetic mutations.
- Trial name
- GENIUS (NCT02000739)
- Testing
- Genetically Informed Therapy
- Where
- United States
- Sponsor
- Dartmouth-Hitchcock Medical Center
Endocrine Tumors, Non-Small Cell Lung Cancer
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are studied to find the parts that make the attack possible.
- Conditions
- Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
- Trial name
- NCT03412877
- Testing
- Cyclophosphamide, Fludarabine, Aldesleukin
- Where
- United States
- Volunteers
- 285 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of vemurafenib and Aldesleukin (interleukin-2) that can be given in combination with interferon alfa-2b in patients with advanced…
- Trial name
- NCT01603212
- Testing
- Vemurafenib, IL-2, Interferon Alpha-2b
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Melanoma, Stage IIA Melanoma
Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
This phase II trial is studying how well saracatinib works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IIA Melanoma, Stage IIB Melanoma, Stage IIC Melanoma
- Trial name
- NCT00669019
- Testing
- saracatinib
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer, Melanoma (Skin)
Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00617799
- Testing
- aldesleukin, gene expression analysis, mutation analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Nebraska
Advanced Solid Tumors Cancer
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
The primary purpose of this Phase 1, open-label study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-368 as a monotherapy and in combination with ABBV-181 in participants with locally advanced or…
- Trial name
- NCT03071757
- Testing
- ABBV-368, ABBV-181
- Where
- 27 sites in United States, France and 4 more
- Volunteers
- 139 people
- Sponsor
- AbbVie
Melanoma Stage Iv, Melanoma Stage Iii
Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain
This is an observational, multicentre epidemiological study with a longitudinal cohort in which information will be retrieved from medical records of patients with advanced metastatic or unresectable melanoma at first diagnosis.
- Conditions
- Melanoma Stage Iv, Melanoma Stage Iii, Advanced Cancer
- Trial name
- GEM-1801 (NCT03605771)
- Testing
- Daily Clinical Practice
- Where
- 39 sites in Spain
- Volunteers
- 400 people
- Sponsor
- Grupo Español Multidisciplinar de Melanoma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.